Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14809436 | 0.82 | KDM4E (0.52) | NOTUMSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2941221 | 0.79 | KDM4E (0.41) | ALDH1A1KDM4E | |
| SCHEMBL11439685 | 0.77 | NOTUM (0.68) | NOTUMSMN1; SMN2TSHRGAAPKM | |
| SCHEMBL27970810 | 0.77 | NOTUM (0.44) | NOTUMSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL14809258 | 0.76 | POLB (0.40) | NOTUMSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL18779900 | 0.76 | SMN1; SMN2 (0.55) | NOTUMSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL27970803 | 0.76 | ALDH1A1 (0.51) | NOTUMSMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL9356553 | 0.71 | ALDH1A1 (0.50) | SMN1; SMN2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL23113066 | 0.71 | CA12 (0.48) | NOTUMSMN1; SMN2ALDH1A1TSHRGAA | |
| SCHEMBL15497044 | 0.70 | ALDH1A1 (0.51) | NOTUMSMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757887-B1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV HEALTHCARE UK LTD (GB) | 2017-04-26 | — | — | EP | disclosed |
| EP-2757887-B1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV HEALTHCARE UK LTD (GB) | 2017-04-26 | — | — | EP | disclosed |
| US-9012642-B2 | Pyrrolopyridinone compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| US-9012642-B2 | Pyrrolopyridinone compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| US-9012642-B2 | Pyrrolopyridinone compounds and methods for treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2015-04-21 | — | — | US | disclosed |
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | VIIV HEALTHCARE UK LIMITED (GB) | 2014-11-20 | — | — | US | disclosed |
| EP-2757887-A1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | VIIV Healthcare UK Limited (GB) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013043553-A1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013043553-A1 | PYRROLOPYRIDINONE COMPOUNDS AND METHODS FOR TREATING HIV | GLAXOSMITHKLINE LLC (US) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343092-A1 | Pyrrolopyridinone Compounds And Methods For Treating HIV | DHPS, PRNP, TYMP | NOTUM 2788/4885SMN1; SMN2 1559/4885MEN1 4374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.